Cidara Therapeutics (NASDAQ: CDTX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.290 | -0.270 | 0.0200 | ||||
REV | 6.110M | 7.109M | 999.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Cidara Therapeutics (NASDAQ: CDTX) through any online brokerage.
Other companies in Cidara Therapeutics’s space includes: Aeglea BioTherapeutics (NASDAQ:AGLE), Virios Therapeutics (NASDAQ:VIRI), Cabaletta Bio (NASDAQ:CABA), Synaptogenix (NASDAQ:SNPX) and Larimar Therapeutics (NASDAQ:LRMR).
The latest price target for Cidara Therapeutics (NASDAQ: CDTX) was reported by HC Wainwright & Co. on Thursday, May 12, 2022. The analyst firm set a price target for 6.00 expecting CDTX to rise to within 12 months (a possible 1236.30% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Cidara Therapeutics (NASDAQ: CDTX) is $0.449 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Cidara Therapeutics.
Cidara Therapeutics’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Cidara Therapeutics.
Cidara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.